We want to demonstrate our commitment to your privacy. In support of the changes to the EU data protection law, we�ve updated our privacy notice effective May 25, 2018.

Arrow Immune is developing next-generation biologics for immuno-oncology in solid tumors. The company is developing protein engineering technology to retain IO molecules in the tumor microenvironment, both to function as monotherapies and to enhance response to checkpoint inhibitor immunotherapy. The company has developed a powerful approach to mask these compounds such that they are inactive in the periphery yet are activated within the tumor, to limit immune-related adverse events and open the therapeutic window.

Jeffrey Hubbell is the Eugene Bell Professor in Tissue Engineering and Deputy Dean for Development at the University of Chicago. A biomolecular engineer and entrepreneur, Hubbell develops materials for use in regenerative medicine and immunology. His research has led to tools and treatments, including nanoparticle vaccines and drug delivery systems, that combat diseases ranging from influenza and type 1 diabetes to tuberculosis and cancer. Hubbell has cofounded five companies, three of which are based on or related to research he directs at the University of Chicago. His companies create surgical sealants and tissue repair agents, and develop technologies to increase immunotolerance. Along with his associates, he holds 77 patents. A member of the National Academy of Engineering, Hubbell is an elected fellow of Biomaterials Science and Engineering, the American Association for the Advancement of Science, and the American Institute of Medical and Biological Engineering. He is a former president of the Society for Biomaterials.